Investor relations

Investor relations

Upcoming events

Third quarter and nine months results 2014

6th November 2014

AstraZeneca will announce third quarter & nine months results for 2014 on Thursday, 6th November with a scheduled Stock Exchange release time of 07:00GMT (08:00CET, 02:00AM EST). An analyst presentation of the results will take place at 12:00GMT (13:00CET, 07:00AM EST).

View event details


AstraZeneca Investor Day

18th November 2014, London

AstraZeneca will host an Investor Day for analysts and Investors to be held on Tuesday 18th November 2014. This will be an opportunity for Pascal Soriot and his management team to provide an updated view of AstraZeneca’s strategy and plans to return to growth and scientific leadership in our chosen areas.

Please contact us for more details or if you are planning to attend the conference.

If you are unable to join the event in person, the presentations will be accessible by live and recorded webcast and teleconference.


Investor Relations presentation

Download our presentation to review our latest financial information, product performance and see progress on our development pipeline of potential new medicines. Updated following our Q2 and half year results 2014.

Investor Relations presentation (PDF 5076kb)

Latest downloads

Second quarter and half year results 2014

31 July 2014

Strategic Transaction with Almirall

30 July 2014

American Society of Clinical Oncology

3 June 2014

American Thoracic Society AstraZeneca Analyst briefing

20 May 2014


Annual Report 2013

AstraZeneca Annual Report 2013

Our Annual Report provides a wide range of information about our global business and how we are working, both within the company and in partnership with others, to push the boundaries of science and deliver medicines that transform the lives of people around the world.


Currency guidance 2014

In order to help analysts and investors estimate the impact of changing exchange rates on sales and earnings, the Company provides an annual 'currency sensitivity guide', alongside the rates upon which its earnings guidance is based.

The latest guide, intended to help estimate the impact of currency movements for 2014, is an update of the 2013 guidance given in January 2013.

View 2014 currency guidance


Keeping investors in touch

Download our iPad app now from the app store

AstraZeneca Investor Relations iPad app

The AstraZeneca Investor Relations iPad app provides instant access to our latest news, webcasts and presentations, events and leadership videos.

Notifications will keep you up to date with the most recent updates from AstraZeneca and synchronise to your device for reference.

Download and install from the iTunes store

Latest press releases

AstraZeneca strengthens partnership with the University of Cambridge
16 October 2014
Positive results from Phase IIb benralizumab study in severe asthma published in The Lancet Respiratory Medicine
9 October 2014
AstraZeneca updates on progress of oncology pipeline at ESMO 2014 congress
27 September 2014
MOVENTIG® (naloxegol) receives positive CHMP opinion in the EU for the treatment of adults with opioid-induced constipation
26 September 2014
IRESSA receives CHMP positive opinion to include blood based diagnostic testing in European label
26 September 2014
MedImmune and Cancer Research UK establish joint CRUK-MEDI Alliance Laboratory to develop new biologic cancer medicines
25 September 2014
Study showed AstraZeneca’s exenatide once-weekly suspension for autoinjection provided superior HbA1c reductions vs. twice-daily exenatide (Byetta®) in adults with type 2 diabetes
19 September 2014
FDA approves MOVANTIK™ (naloxegol) tablets C-II for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain
16 September 2014
AstraZeneca and Lilly announce alliance to develop and commercialise BACE inhibitor AZD3293 for Alzheimer’s disease
16 September 2014
AstraZeneca to present research from its innovative diabetes portfolio at the 2014 Meeting of the European Association for the Study of Diabetes
10 September 2014
Benralizumab Phase II COPD study published in The Lancet Respiratory Medicine
8 September 2014
New data indicates Brilinta/Brilique™ has the flexibility to be initiated pre-hospital or in hospital in STEMI patients
1 September 2014

Share price

London
43.16 GBP
New York
68.78 USD
Stockholm
504.00 SEK

At 23-10-2014 01:32 GMT

Detailed share price


Stock symbol - AZN

On LSE, NYE and OMX